C3 Glomerulopathy
C3 glomerulopathy (C3G) is a rare kidney disease characterized by the abnormal deposition of complement component C3 in the glomeruli, leading to kidney damage and potential kidney failure.
C3-Glomerulopathy: Testing CPV-104
We are examining the safety and how the body processes CPV-104 in healthy individuals and patients with C3-Glomerulopathy. This study aims to gather important information about this new treatment.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Medical University Of Vienna
Universitätsklinik für Klinische Pharmakologie
Vienna, Austria
Cliniques universitaires Saint-Luc
Rare Kidney Disease Clinic
Sint-Stevens-Woluwe, Belgium
Fakultni Thomayerova nemocnice
Clinical Pharmacology Unit.
Prague, Czechia
Sponsor: Eleva GmbH
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.